Phaseline

Companies › Zelluna Immunotherapy

Zelluna Immunotherapy: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ZI-MA4-1
Allogeneic TCR-engineered NK cells targeting MAGE-A4
MAGEA4Phase 1Ovarian CancerDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07613723ZI-MA4-1Phase 1Ovarian CancerOncologyDec 2028

Targets

MAGEA4 (1)

Companies with the same targets

PDC*line Pharma SAS CDR-Life USWM CT

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.